Last reviewed · How we verify

Levobupivacaine 0.5% + epinephrin 1/200000

University Hospital, Antwerp · FDA-approved active Small molecule

Levobupivacaine 0.5% + epinephrin 1/200000 is a Local anesthetic with vasoconstrictor Small molecule drug developed by University Hospital, Antwerp. It is currently FDA-approved for Local and regional anesthesia for surgical and dental procedures, Infiltration anesthesia, Nerve blocks. Also known as: Chirocaine.

Levobupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption.

Levobupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption. Used for Local and regional anesthesia for surgical and dental procedures, Infiltration anesthesia, Nerve blocks.

At a glance

Generic nameLevobupivacaine 0.5% + epinephrin 1/200000
Also known asChirocaine
SponsorUniversity Hospital, Antwerp
Drug classLocal anesthetic with vasoconstrictor
TargetVoltage-gated sodium channels; alpha-adrenergic receptors
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Levobupivacaine is the S-enantiomer of bupivacaine, a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve fibers, preventing depolarization and action potential propagation. The addition of epinephrine (1:200,000) acts as a vasopressor, reducing blood flow to the injection site, which decreases systemic toxicity and extends the duration of local anesthesia by slowing drug clearance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Levobupivacaine 0.5% + epinephrin 1/200000

What is Levobupivacaine 0.5% + epinephrin 1/200000?

Levobupivacaine 0.5% + epinephrin 1/200000 is a Local anesthetic with vasoconstrictor drug developed by University Hospital, Antwerp, indicated for Local and regional anesthesia for surgical and dental procedures, Infiltration anesthesia, Nerve blocks.

How does Levobupivacaine 0.5% + epinephrin 1/200000 work?

Levobupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption.

What is Levobupivacaine 0.5% + epinephrin 1/200000 used for?

Levobupivacaine 0.5% + epinephrin 1/200000 is indicated for Local and regional anesthesia for surgical and dental procedures, Infiltration anesthesia, Nerve blocks.

Who makes Levobupivacaine 0.5% + epinephrin 1/200000?

Levobupivacaine 0.5% + epinephrin 1/200000 is developed and marketed by University Hospital, Antwerp (see full University Hospital, Antwerp pipeline at /company/university-hospital-antwerp).

Is Levobupivacaine 0.5% + epinephrin 1/200000 also known as anything else?

Levobupivacaine 0.5% + epinephrin 1/200000 is also known as Chirocaine.

What drug class is Levobupivacaine 0.5% + epinephrin 1/200000 in?

Levobupivacaine 0.5% + epinephrin 1/200000 belongs to the Local anesthetic with vasoconstrictor class. See all Local anesthetic with vasoconstrictor drugs at /class/local-anesthetic-with-vasoconstrictor.

What development phase is Levobupivacaine 0.5% + epinephrin 1/200000 in?

Levobupivacaine 0.5% + epinephrin 1/200000 is FDA-approved (marketed).

What are the side effects of Levobupivacaine 0.5% + epinephrin 1/200000?

Common side effects of Levobupivacaine 0.5% + epinephrin 1/200000 include Transient paresthesia, Hypotension, Tachycardia, Headache, Nausea, CNS toxicity (at high doses).

What does Levobupivacaine 0.5% + epinephrin 1/200000 target?

Levobupivacaine 0.5% + epinephrin 1/200000 targets Voltage-gated sodium channels; alpha-adrenergic receptors and is a Local anesthetic with vasoconstrictor.

Related